Results 161 to 170 of about 11,121 (203)

The Role of Histone Methylation in Heart Failure: Epigenetic Mechanisms and Therapeutic Perspectives. [PDF]

open access: yesDrug Des Devel Ther
Zhou Y   +9 more
europepmc   +1 more source

Phenotype-dependent subtyping exposes high MYC activity as a targetable dependency in LuAd

open access: yes
Laing S   +28 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

G9a - An Appealing Antineoplastic Target

Current Cancer Drug Targets, 2017
G9a is the primary enzyme for mono- and dimethylation at Lys 9 of histone H3 and forms predominantly the heteromeric complex as a G9a-GLP (G9a-like protein) that is a functional histone lysine methltransferase in vivo. Mounting evidence suggests that G9a catalyzes methylation of histone and nonhistone proteins, which plays a crucial role in diverse ...
Haopeng Sun, Qidong You, Xiaoke Guo
exaly   +3 more sources

Targeting EHMT2/ G9a for cancer therapy: Progress and perspective

European Journal of Pharmacology, 2021
Euchromatic histone lysine methyltransferase-2, also known as G9a, is a ubiquitously expressed SET domain-containing histone lysine methyltransferase linked with both facultative and constitutive heterochromatin formation and transcriptional repression.
Suraya, Jan   +6 more
openaire   +2 more sources

Recently Discovered Ezh2 and Ehmt2 (G9A) Inhibitors

Future Medicinal Chemistry, 2016
Methyltransferase enzymes are promising epigenetic oncotargets. Recent efforts toward the development of inhibitors of two methyltransferases, EZH2 and G9a, as potential anticancer therapies are reviewed with a focus on the structure-activity relationships of compounds published from 2012.
Uttara, Soumyanarayanan, Brian W, Dymock
openaire   +2 more sources

Home - About - Disclaimer - Privacy